Khater A, El-Anwar MW, Nofal AA, Elbahrawy AT, et al.
International archives of otorhinolaryngology. Date of publication 2018 Jul 1;volume 22(3):245-249.
1. Int Arch Otorhinolaryngol. 2018 Jul;22(3):245-249. doi: 10.1055/s-0037-1605376.
Epub 2017 Sep 12.
Sudden Sensorineural Hearing Loss: Comparative Study of Different Treatment
Modalities.
Khater A(1), El-Anwar MW(1), Nofal AA(1), Elbahrawy AT(1).
Author information:
(1)Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine,
Zagazig University, Zagazig, Egypt.
Introduction Idiopathic sudden sensorineural hearing loss (ISSNHL) is hearing
loss of at least 30 dB in at least 3 contiguous frequencies within at least 72
hours. There are many different theories to explain it, and many different
modalities are used for its management, such as: systemic steroids (SSs),
intratympanic steroid injection (ITSI), hyperbaric oxygen therapy (HOT),
antiviral drugs, and vasodilators or vasoactive substances. Objectives This
study aims to evaluate the efficacy of the combination of the most common
treatment modalities of ISSNHL and to compare the results if HOT was not one of
the treatment modalities administered. Methods The study was conducted with 22
ISSNHL patients with ages ranging from 34 to 58 years. The patients were divided
into 2 groups; group A included 11 patients managed by SSs, ITSI, antiviral
therapy, and HOT simultaneously, and group B included 11 patients exposed to the
aforementioned modalities, with the exception of HOT. Results After one month,
all of the patients in group A showed total improvement in hearing in all
frequencies, with pure tone average (PTA) of 18.1 ± 2.2, while in group B, 5/11
(45.5%) patients showed total improvement, and 6 /11 (54.5%) patients showed
partial improvement, with a total mean PTA of 28.1 ± 8.7. Conclusion The early
administration of HOT in combination with other clinically approved modalities
(SSs, ITSI, antiviral therapy) provides better results than the administration of
the same modalities, with the exception of HOT, in the treatment of ISSNHL.
DOI: 10.1055/s-0037-1605376
PMCID: PMC6033594
PMID: 29983762
